suspected leukocytoclastic vasculitis; red spots on legs; This serious case was reported by a consumer via call center representative and described the occurrence of leukocytoclastic vasculitis in a female patient who received Flu Seasonal TIV Dresden (Fluarix 2024-2025 season) (batch number T74KG) for prophylaxis. On an unknown date, the patient received Fluarix 2024-2025 season. On an unknown date, 7 days after receiving Fluarix 2024-2025 season, the patient experienced leukocytoclastic vasculitis (Verbatim: suspected leukocytoclastic vasculitis) (serious criteria GSK medically significant) and red spotty rash (Verbatim: red spots on legs). The outcome of the leukocytoclastic vasculitis was not reported and the outcome of the red spotty rash was unknown. It was unknown if the reporter considered the leukocytoclastic vasculitis and red spotty rash to be related to Fluarix 2024-2025 season and Fluarix Pre-Filled Syringe Device. The company considered the leukocytoclastic vasculitis to be unrelated to Fluarix 2024-2025 season and Fluarix Pre-Filled Syringe Device. It was unknown if the company considered the red spotty rash to be related to Fluarix 2024-2025 season and Fluarix Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 14-JAN-2025 Reporter was the patient’s father. Patient developed red spots on the legs 7 days after receiving the Fluarix vaccine. Reporter suspected that the patient developed Leukocytoclastic vasculitis (LCV).; Sender’s Comments: Cutaneous vasculitis is an unlisted event which is considered unrelated to GSK vaccine Fluarix 2024-2025 season and Fluarix PRE-FILLED SYRINGE DEVICE.